Haleon 過去の業績

過去基準チェック /26

Haleonは、平均年間2.7%の収益成長を遂げていますが、 Personal Products業界の収益は、年間成長しています。収益は、平均年間11.7% 5.7%収益成長率で成長しています。 Haleonの自己資本利益率は7.5%であり、純利益率は10.7%です。

主要情報

2.7%

収益成長率

-5.0%

EPS成長率

Personal Products 業界の成長	20.9%
収益成長率	5.7%
株主資本利益率	7.5%
ネット・マージン	10.7%
次回の業績アップデート	27 Feb 2025

Recent updates

収支内訳

Haleon の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NYSE:HLN 収益、費用、利益 ( )GBP Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	11,240	1,208	4,314	300
30 Jun 24	11,258	1,088	4,312	299
31 Mar 24	11,235	1,083	4,258	293
31 Dec 23	11,302	1,049	4,288	297
30 Sep 23	11,314	1,250	4,145	302
30 Jun 23	11,408	1,230	4,293	307
31 Mar 23	11,217	1,106	4,084	314
31 Dec 22	10,858	1,060	4,060	303
30 Sep 22	10,560	1,390	4,183	302
30 Jun 22	10,158	1,416	3,656	282
31 Mar 22	9,866	1,500	3,923	270
31 Dec 21	9,545	1,390	3,793	248
31 Dec 20	9,892	1,145	3,832	296
31 Dec 19	8,480	655	3,357	267

質の高い収益: HLNは高品質の収益を持っています。

利益率の向上: HLNの現在の純利益率 (10.7%)は、昨年(11%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: HLNの収益は過去 5 年間で年間2.7%増加しました。

成長の加速: HLNは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: HLNは過去 1 年間で収益成長率がマイナス ( -3.4% ) となったため、 Personal Products業界平均 ( 22.2% ) と比較することが困難です。

株主資本利益率

高いROE: HLNの自己資本利益率 ( 7.5% ) は低いとみなされます。

Haleon 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Haleon plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Haleon plc to Report First Half, 2022 Results on Sep 19, 2022

Recent updates

Haleon: Tailwinds Are Mostly Priced In

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 455,701,825 shares, representing 4.99% of its issued share capital., under the authorization approved on May 8, 2024.

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Dr. Reddy'S Laboratories S.A. completed the acquisition of Northstar Switzerland SARL from Haleon plc (LSE:HLN).

Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Haleon plc Announces Directorate Change

Haleon plc Announces Chief Financial Officer Changes

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel'

Haleon plc, Annual General Meeting, May 08, 2024

Haleon plc Proposes Final Dividend for Fiscal Year 2023, Payable on 16 May 2024

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Haleon plc to Report Fiscal Year 2023 Results on Feb 29, 2024

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon Reportedly Exploring Sale of Nicotine Gum Business

Haleon: A Hidden Gem In The Consumer Health Market

Haleon exploring sale of ChapStick Brand - report

Haleon plc Announces Board Changes

Haleon said to evaluate potential deals to increase its size - report

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon: Undervalued With Clear Catalyst Ahead

Former GSK consumer health unit Haleon hits all-time low

Haleon Introduces Advil PLUS Acetaminophen to Canadians, Combining Two Trusted Pain Relievers into One Convenient Tablet

Haleon plc to Report First Half, 2022 Results on Sep 19, 2022

Haleon CEO says brand recognition, gross margins will drive growth - CNBC

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /26